Contrasting Regenicin (OTCMKTS:RGIN) & Nyxoah (NASDAQ:NYXH)

Regenicin (OTCMKTS:RGIN) and Nyxoah (NASDAQ:NYXH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

Insider & Institutional Ownership

0.0% of Regenicin shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Regenicin and Nyxoah, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regenicin	0	0	0	0	N/A
Nyxoah	0	1	5	0	2.83

Nyxoah has a consensus target price of $20.20, suggesting a potential upside of 96.31%.

Volatility & Risk

Regenicin has a beta of -17.47, indicating that its share price is 1,847% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500.

Profitability

This table compares Regenicin and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regenicin	N/A	N/A	N/A
Nyxoah	-843.49%	-42.14%	-33.55%

Valuation and Earnings

This table compares Regenicin and Nyxoah’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regenicin	N/A	N/A	-$640,000.00	N/A	N/A
Nyxoah	$4.70 million	N/A	-$46.77 million	($1.64)	-6.27

Regenicin has higher earnings, but lower revenue than Nyxoah.

Summary

Regenicin beats Nyxoah on 5 of the 8 factors compared between the two stocks.

About Regenicin

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.